The B cell in systemic lupus erythaematosus: a rational target for more effective therapy.
Current treatment options for systemic lupus erythaematosus (SLE) are diverse and poorly defined, and aggressive therapy can be associated with serious toxicity and tolerability issues. There is, therefore, a need for new and improved treatments to be studied thoroughly in well-designed controlled trials. B Cell dysfunction has emerged as a key pathophysiological component of SLE and is a prime target for the development of new agents for a wide range of lupus severity, including advanced disease. Although many current drugs appear to modify B cell function, the advent of new, targeted therapies offers the hope of improved efficacy and a better long-term tolerability profile.
Driver
C B
CB
Cedars-Sinai Medical Center, Los Angeles, California 90048, USA.
Ishimori
M
M
Weisman
M H
MH
D000818:Animals; D015703:Antigens, CD / Q000187:drug effects; D001402:B-Lymphocytes / Q000187:drug effects / Q000502:physiology*; D004195:Disease Models, Animal; D006801:Humans; D007108:Immune Tolerance; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology*; D008212:Lymphocyte Depletion / Q000379:methods; D051379:Mice
D015703:Antigens, CD; D007166:Immunosuppressive Agents